Vericel (VCEL) Expected to Post Earnings on Thursday

Vericel (NASDAQ:VCEL) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $0.0575 per share and revenue of $77.95 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm had revenue of $77.46 million during the quarter, compared to analysts’ expectations of $72.70 million. During the same period in the previous year, the company earned ($0.01) earnings per share. The company’s revenue was up 22.5% compared to the same quarter last year. On average, analysts expect Vericel to post $0.54 EPS for the current fiscal year and $0.84 EPS for the next fiscal year.

Vericel Stock Down 5.0%

Shares of VCEL opened at $41.09 on Thursday. The company’s fifty day moving average is $40.63 and its 200-day moving average is $38.62. Vericel has a 12 month low of $28.95 and a 12 month high of $49.32. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 87.43 and a beta of 1.02.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on VCEL shares. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a report on Thursday, July 30th. Truist Financial lowered their target price on shares of Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Vericel in a report on Tuesday, July 28th. TD Cowen boosted their price target on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and an average price target of $57.20.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.